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Heart failure (HF) is a major public health problem and a leading cause of hospitali-
zation in western countries. Over the past decades, the goal has been to find the
best method for monitoring congestive symptoms to prevent hospitalizations.
Addressing this task through regular physician visits, blood tests, and imaging has
proven insufficient for optimal control and has not decreased enough HF-related hos-
pitalization rates. In recent years, new devices have been developed for this reason
and CardioMEMS is one of the therapeutic monitoring options. CardioMEMS has shown
to be effective in preventing and reducing HF hospitalizations in patients both with
HF with reduced ejection fraction and HF with preserved ejection fraction.
CardioMEMS’ versatility has made it a great option for pulmonary artery pressure
monitoring, both during the coronavirus disease-19 (COVID-19) pandemic and when
the clinic visits have (partially) resumed. CardioMEMS is the remote haemodynamic
monitoring system with the most evidence-driven efficacy, and COVID-19 has put it
in the spot as a centre-stage technology for HF monitoring. In a few months of the
COVID-19 epidemic, CardioMEMS has grown to maturity, making it the new normal
for high-quality, high-value remote HF care.
Heart failure hospitalizations—a major
public health problem
Heart failure (HF) is a major public health problem and a
leading cause of hospitalization in western countries. The
prevalence of HF is approximately 1–2% in the adult popula-
tion in developed countries, rising to 10% among people
>70years of age. Among people >65years of age present-
ing to primary care with breathlessness on exertion, one in
six will have unrecognized HF (mainly HF with preserved
ejection fraction, HFpEF).1 Since the earliest cases of coro-
navirus disease-2019 (COVID-19) infection were reported,
our care delivery systems have been challenged in unprece-
dented ways, affecting all patients with cardiovascular pa-
thologies, but fundamentally those with HF.2
The aim of the management of HF is to maintain the
pumping function of the heart and prevent progression to
decompensated HF, which is the most common cause of
hospitalization in HF patients. Improvements in treatments
and their implementation have improved survival and re-
duced the hospitalization rate in patients with HF with re-
duced ejection fraction (HFrEF),1 although outcomes are
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still often unsatisfactory. The most recent European data
(ESC-HF pilot study) demonstrate that 12-month all-cause
mortality rates for hospitalized and stable/ambulatory HF
patients were 17% and 7%, respectively, and the 12-month
hospitalization rates were 44% and 32%, respectively.3 Over
the past decades, the goal has been to find the best
method for monitoring congestive symptoms to prevent
hospitalizations. Addressing this task through regular physi-
cian visits, blood tests, and imaging has proven insufficient
for optimal control and has not decreased enough HF-
related hospitalization rates. Hopes were set on circulating
biomarkers, but even N-terminal pro-brain natriuretic pep-
tide, which is an important new diagnostic and prognostic
tool, cannot reliably predict mortality or overall hospitali-
zation rates.4 Numerous prognostic markers of death and/
or HF hospitalization have been identified in patients with
HF. More recently, several multivariable prognostic risk
scores have been developed for different populations of
patients with HF,5–7 and some are available as interactive
online applications. Multivariable risk scores have been de-
veloped to help predict death in patients with HF, but in
general, they remain less useful for the prediction of subse-
quent HF hospitalizations.6,7
Long before the COVID-19 pandemic altered our lives,
remote monitoring emerged as a viable way to overcome
the long interval between office visits, monitor patients re-
motely, and keep them safe by identifying disease progres-
sion in time to prevent hospitalization. Non-invasive
methods of monitoring HF patients, such as consistent
scheduled phone calls with patients and transfer of physio-
logic data through electronic devices, have been studied
but have not had significant impact on mortality or hospi-
talization rates.8–12 Numerous clinical trials have been con-
ducted to assess the impact of implantable cardiac
electronic devices in the management of HF and early de-
tection of congestive symptoms (e.g. intrathoracic imped-
ance), but the results are equivocal and not precise enough
to allow early detection of fluid retention and timely man-
agement.13–15 In sum, non-haemodynamic-based remote
monitoring has not proven to reduce HF hospitalization.
Haemodynamic monitoring using
CardioMEMS
Continuous monitoring of pulmonary artery pressure (PAP)
could be used as an indicator of HF andwould allow optimal
monitoring and timely management before the occurrence
of symptomatic, acutely decompensated HF.16 The
CardioMEMS device was created for this purpose and ap-
proved by the Food and Drug Administration (FDA) in 2014
to help monitor PAP and send the data on daily basis to pro-
viders, allowing timely management of HF to help lower
the hospitalization rate.17
The CardioMEMS is a wireless pressure-sensitive device
that uses microelectromechanical systems (MEMS) technol-
ogy. It consists of an implantable HF sensor, a delivery cath-
eter, and an electronic monitoring unit. Using right heart
catheterization, the device is implanted in the distal left
posterior pulmonary artery. The device measures the pul-
monary arterial pressure through ambient atmospheric
pressure changes detected by its barometer. CardioMEMS
does not have any batteries or leads and is powered by an
external antenna and radiofrequency signals. The elec-
tronic unit transmits the PAP measurements daily. These
data can be used by physicians to adjust the HF therapy
(mainly through adjusting the diuretic dose) before conges-
tive symptoms develop, ultimately resulting in lower hospi-
talization rates.18
The goal of the CHAMPION trial (CardioMEMS Heart
Sensor Allows Monitoring of Pressures to Improve Outcomes
in New York Heart Association (NYHA) Functional Class III
Heart Failure Patients) was to determine if physicians could
reduce HF hospitalizations by managing patient PAP using
the CardioMEMS HF System.18 The trial, published almost a
decade ago, met its primary efficacy endpoint of reduction
in the rate of HF hospitalizations, with the treatment arm
having 28% fewer HF hospitalizations compared with the
control arm at 6months. Men and women in the treatment
group had similar HF hospitalization rates. The CHAMPION
trial also met its secondary efficacy endpoints, with the
treatment arm having lower PAP, fewer days in the hospi-
tal, and better quality of life compared with the control
arm. Over the entire randomized follow-up in the 1.5-year
trial, treatment-group patients had 33% fewer HF hospital-
izations than control group patients. For every 100 patients
treated, 23 HF hospitalizations were prevented per year.
The current recommendation for CardioMEMS use is in
NYHA Class III HF patients who have been hospitalized for
HF within 1 year prior to implantation. An important vari-
able in the assessment of CardioMEMS’ effectiveness in re-
ducing hospitalization is the 30-day rate of readmission.
Adamson et al.19 showed that medications were changed
more often in the treatment group compared with the con-
trol group and that the overall rate of hospitalization was
49% lower in the treatment than in the control group. It
was also determined that all-cause 30-day readmissions
were 58% lower in the treatment group. Subset analysis of
the CHAMPION trial has shown that the sensor can also lead
to better haemodynamic management of patients
with preserved ejection fraction and lower rates of
Figure 1 Active patients and percentage of patients meeting custom thresholds within EMEA included in Merlin.net data as of June 2020.
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hospitalization when compared with standard therapy.20 A
recently published post-approval study of 1200 patients in
multiple practice settings demonstrated a 58% reduction in
HF hospitalizations and a 28% reduction in all-cause hospi-
talizations during the year after implantation of
CardioMEMS.21
An economic analysis of data from the CHAMPION trial
showed an incremental cost-effectiveness ratio based on
all-cause comprehensive management of HF patients of
$29,593 per quality-adjusted life-year gained when the
patients were managed with PAP monitoring;22 these anal-
yses indicate that the CardioMEMS HF System is a cost-
effective solution.
Singh et al.23 showed, before the COVID-19 pandemic in-
vaded us, that despite its well-established beneficial clini-
cal outcomes in the management of HF patients, adoption
of CardioMEMS was slow and among their patient popula-
tion only 21% of patients eligible for the device received it.
CardioMEMS and COVID-19
The COVID-19 pandemic has significantly impacted
patients with HF and their care delivery systems. To reduce
severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) transmission, health systems have largely transi-
tioned to noncontact care delivery methods for ambulatory
care. DeFilippis et al.24 indicate that such services may in-
clude telehealth visits, during which an audiovisual tele-
communication system is used; virtual check-ins between
the patient and provider via telephone or another device,
which are conducted to decide whether additional services
are needed; and electronic visits (‘e-visits’), which are
communications between patients and providers through
an online portal. Of note, despite the well-established fea-
sibility and safety of these telemedicine systems for
patients with HF, their use has not yet been reliably associ-
ated with a reduction in emergency department visits or
hospitalizations.8–12 Importantly, the option for in-person
clinic visits should remain available for patients without ac-
cess to telemedicine services, high-risk patients (e.g.
patients on continuous inotropes), and those for whom
physical examination is critical for clinical decision-
making.
Telemonitoring through PAP monitoring and biosensing
devices has been adopted quickly during the COVID-19
pandemic to provide better assessment of HF clinical sta-
tus, while maintaining social distancing through the perfor-
mance of virtual visits. As pointed out by Abraham et al.,25
these systems accompanied by their dedicated cloud-
based information management are no longer the future
but the present of improved HF care. The authors suggest,
as a first step for implementation, that high-risk patients
at home and in settings like nursing homes might be the
first recipients of such technology-driven remote HF
assessment.
It is highly likely that these indications will expand
quickly to lower-risk patients as both patients and physi-
cians become more familiar with the added value of hae-
modynamic remote monitoring. Indeed, a remarkable
increase in the number of CardioMEMS active patients has
been observed in Europe, the Middle East, and Africa
(EMEA) during the first semester of 2020, up from 706 ac-
tive patients in January to 766 in June (Figure 1).
Furthermore, during the high peak of the first wave of
SARS-CoV-2 infections, a substantial decrease in hospital-
izations was identified among HF patients with implanted
CardioMEMS devices. Additional confounders during the
pandemic must be taken in consideration, including pa-
tient fear and legally imposed restricted mobilisation, and
it would be incorrect to attribute this entirely to
CardioMEMS. Figure 2 illustrates the number of patients
that required hospitalizations out of all active patients
within EMEA included in Merlin.net data as of June 2020. Of
note, CardioMEMS, as other telemedicine systems, can
help to manage HF patients outside of the hospital setting
during a pandemic but this should not be the exclusive rec-
ommendation, as discussed above.
Conclusions
To conclude, due to both the ever-increasing costs associ-
ated with health care admissions and the social distancing
imposed by COVID-19, finding solutions for better monitor-
ing of HF has become imperative. In recent years a series of
new devices has been created for this reason and
CardioMEMS is one of the therapeutic monitoring options.
CardioMEMS has been shown to be effective in preventing
and reducing HF hospitalizations in patients with HFrEF and
HFpEF. CardioMEMS’ versatility has made it a great option
for PAP monitoring, both during the pandemic and when
clinic visits resume. CardioMEMS is the remote haemody-
namic monitoring system with the most evidence-driven
efficacy, and COVID-19 has put it in the spot as a centre-
stage technology for HF monitoring. In a few months of the
COVID-19 epidemic, CardioMEMS has grown to maturity
more than it had in the past decade, making it the new nor-
mal for high-quality, high-value remote HF care.
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Figure 2 Number of patients that required hospitalization out of all ac-
tive patients within EMEA included in Merlin.net data as of June 2020.
Remarkably, despite the peak of the COVID-19 pandemic in Europe during
the months of March, April, and May, a clear decrease in hospitalizations
was observed.
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